Latest news with #TDCowen
Yahoo
2 hours ago
- Health
- Yahoo
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron and Scholar Rock. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week. Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren. Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss. Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval. "We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said. Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said. Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Business
- Yahoo
Why Credo Technology Stock Was Marching Higher This Week
An analyst raised his price target on the highly specialized tech company. He maintained his buy recommendation as he did so. 10 stocks we like better than Credo Technology Group › Data center connectivity solutions company Credo Technology (NASDAQ: CRDO) won attention from many stock market participants this week, thanks in no small part to an analyst flagging it as a top pick in the small and mid-cap categories. With this pleasant tailwind at its back, Credo's share price was a robust 16%-plus higher as of late Thursday night, according to data compiled by S&P Global Market Intelligence. The pundit behind the price target boost was TD Cowen's Joshua Buchalter, who on Wednesday upped his fair value assessment on Credo stock to $95 per share; previously he had tagged it as potentially being worth $85. In making the change he left his buy rating intact. Not only that; according to reports, Buchalter and TD Cowen now consider Credo his company's best small- or mid-cap idea for 2025. That's meaningful, given the many stocks in those two categories. In his Credo update, the analyst was particularly enthusiastic about the effect of artificial intelligence (AI) demand on Credo's business. Many companies are racing to enhance their products and services with AI functionalities, and data centers must upgrade to handle the huge resource needs of the technology. It hasn't escaped Buchalter's notice that Credo is also a high-growth and high-margin company, and it's entirely possible that management will be able to maintain (or even exceed) the torrid growth it has shown of late. This company's stock is a fine buy on the continued rise of AI, and the prognosticator's optimism is justified. Before you buy stock in Credo Technology Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Credo Technology Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Credo Technology Stock Was Marching Higher This Week was originally published by The Motley Fool
Yahoo
8 hours ago
- Business
- Yahoo
TD Cowen Remains Bullish on MicroStrategy (MSTR)
MicroStrategy Incorporated (NASDAQ:MSTR) is one of the 13 Crypto Stocks with the Highest Upside Potential. On June 17, TD Cowen analyst Lance Vitanza maintained a Buy rating on MicroStrategy Incorporated (NASDAQ:MSTR) with a price target of $590. The rating update came after MicroStrategy Incorporated (NASDAQ:MSTR) announced that it acquired 10,100 Bitcoins in the June 9 to June 15 period for around $1.05 billion. The average price of the Bitcoins came up to $104,080 per bitcoin, as per Strategy's 8-K filing with the US Securities and Exchange Commission (SEC). After the acquisition, the company holds 592,100 Bitcoins at an average price of $70,666, collectively valued at over $63 billion. A software engineer wearing a headset, collaborating with a remote team on a project. MicroStrategy Incorporated (NASDAQ:MSTR) spent around $41.84 billion to acquire these Bitcoins and conducted the latest acquisition using the proceeds from its preferred share offering. The company's total Bitcoin holdings now represent around 2.8% of the total Bitcoin supply of 21 million. MicroStrategy Incorporated (NASDAQ:MSTR) engages in the development of the Bitcoin network through its operations in technology, financial markets, and advocacy. It is the world's largest corporate holder of Bitcoin. While we acknowledge the potential of MSTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Business
- Yahoo
Celsius Holdings (CELH) Upgraded by TD Cowen; Sees 30% Distribution Boost Ahead
Celsius Holdings (CELH, Financials) was upgraded to Buy by TD Cowen on Monday, with analysts raising their price target to $55 and projecting a 30% increase in distribution points under PepsiCo (PEP, Financials). They expect the stock to keep climbing this year as momentum builds across product lines. Warning! GuruFocus has detected 4 Warning Signs with NVDA. In the note, TD Cowen said Celsius has turned the corner; scanner sales have improved from earlier declines, helped by fresh product launches and the marketing campaign. Shelf space has grown 15%20% following spring resets; further gains are expected through PepsiCo's network, which helped Celsius expand TDPs by 60% within six months of onboarding. The Alani Nu integration is also shaping up well; sales have more than doubled, and the customer base overlaps only modestly with Celsiusjust 14%, according to household data. Analysts said the low overlap limits cannibalization and creates new growth opportunities; the price paid was attractive, further limiting downside risk. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
10 hours ago
- Business
- Business Insider
TD Cowen Reaffirms Their Buy Rating on AGF Management B NV (AGF.B)
TD Cowen analyst Graham Ryding maintained a Buy rating on AGF Management B NV (AGF.B – Research Report) yesterday and set a price target of C$15.00. The company's shares closed yesterday at C$12.40. Confident Investing Starts Here: Ryding covers the Financial sector, focusing on stocks such as AGF Management B NV, goeasy, and Power Corp of Canada. According to TipRanks, Ryding has an average return of 16.9% and a 72.31% success rate on recommended stocks. In addition to TD Cowen, AGF Management B NV also received a Buy from Desjardins's Gary Ho in a report issued on June 17. However, on the same day, BMO Capital maintained a Hold rating on AGF Management B NV (TSX: AGF.B). The company has a one-year high of C$12.46 and a one-year low of C$7.37. Currently, AGF Management B NV has an average volume of 60.61K. Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AGF.B in relation to earlier this year.
